Treatment
HS-20093 clinical trials
We’re tracking 13 recruiting studies that include HS-20093, each written for real people, not researchers, below.
Recruiting studies
- NCT06621563RecruitingPhase 1
Study of HS-20117 Combination Therapy for Advanced Solid Tumors
This early-phase trial tests a new drug (HS-20117) combined with other drugs for people with advanced solid tumors. It aims to see if the combination is safe and effective, especially for cancers that have not responded to other treatments.
TianjinAges 18–75 - NCT06769425RecruitingPhase 1
Combination treatment for advanced solid tumors
This trial tests a new combination treatment for people with advanced solid tumors that have not responded to standard therapy. It aims to find a safe dose and see if the combination can shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07186452RecruitingPhase 1
Testing HS-20093 with itraconazole in advanced solid tumors
This trial checks if a drug called itraconazole affects how your body processes another drug, HS-20093. It is for people with advanced solid tumors who have tried standard treatments or cannot tolerate them.
Changsha, HunanAges 18 years+ - NCT07230106RecruitingPhase 2
Study of 3 drugs for men with prostate cancer
This trial tests whether a combination of three new drugs (SHR3680, HS-20093, and SHR2554) can help slow or stop prostate cancer growth. It is for men who are already on hormone therapy and whose PSA level is still rising.
Nanjing, JiangsuAges 18–80 - NCT06332170RecruitingPhase 1
HS-20093 combination safety study for advanced solid tumors
This study tests a new combination drug called HS-20093 for people with advanced solid tumors. It aims to see if it is safe and works against cancer that hasn't responded to other treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07115446RecruitingPhase 1
Study of HS-20093 and HRS-5041 for advanced prostate cancer
This trial tests a combination of two experimental drugs, HS-20093 and HRS-5041, for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if this new treatment can help control the cancer when other treatments have stopped working.
ShanghaiAges 18 years+ - NCT05830123RecruitingPhase 2
Test drug HS-20093 for osteosarcoma after earlier treatment
This Phase 2 trial studies HS-20093 in adults with osteosarcoma or other sarcomas that came back or did not respond to standard treatment. It aims to see how well the drug works and whether it is safe for people whose cancer has progressed.
BeijingAges 18 years+ - NCT06825624RecruitingPhase 1
Testing HS-20093 combinations for advanced colorectal cancer
This trial tests a new drug combination (HS-20093) for people with advanced colorectal cancer that has spread or cannot be removed by surgery. It aims to see if the combination is safe and effective.
Hangzhou, ZhejiangAges 18 years+ - NCT06112704RecruitingPhase 2
HS-20093 for advanced esophageal and other solid tumors
This trial tests an investigational drug called HS-20093 for people with advanced esophageal cancer or other solid tumors that have not responded to prior treatment. The drug targets a protein on cancer cells called B7-H3, and the study aims to see if it can shrink tumors or slow their growth.
Hefei, AnhuiAges 18 years+ - NCT07462923RecruitingPhase 1
A study of HS-20093 for advanced stomach or gastroesophageal cancer
This trial tests a new drug, HS-20093, in people with advanced stomach or gastroesophageal junction cancer that has not responded to other treatments. The goal is to see if it can help shrink or slow the growth of the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06498479RecruitingPhase 3
Comparing a new drug to topotecan for relapsed small cell lung cancer
This trial tests a new drug called HS-20093 against a standard drug (topotecan) for people with small cell lung cancer that has returned after initial treatment. The goal is to see which drug works better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06007729RecruitingPhase 2
A study of HS-20093 for head and neck cancer and other solid tumors
This trial tests a new drug, HS-20093, in people with head and neck squamous cell carcinoma or other solid tumors that have worsened after standard treatments. The goal is to see if the drug can help shrink or slow the growth of these cancers.
Hefei, AnhuiAges 18 years+ - NCT06001255RecruitingPhase 2
Testing HS-20093 for advanced prostate and other solid cancers
This trial is testing a new drug called HS-20093 for people with advanced prostate cancer or other solid tumors that have spread and stopped responding to standard treatments. The drug targets a protein on cancer cells to try to stop cancer growth.
BeijingAges 18 years+
What HS-20093 is being studied for
Conditions with recruiting HS-20093 studies.
Common questions
- Are there clinical trials studying HS-20093?
- Yes. Clin2 currently lists 13 recruiting studies that include HS-20093, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a HS-20093 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is HS-20093 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether HS-20093 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.